{"id":348286,"date":"2025-08-25T14:19:55","date_gmt":"2025-08-25T14:19:55","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-novocure-limited\/"},"modified":"2025-08-25T14:19:55","modified_gmt":"2025-08-25T14:19:55","slug":"how-to-buy-novocure-limited","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/","title":{"rendered":"How to buy NovoCure Limited (NVCR) shares &#8211; Investment in NovoCure Limited (NVCR) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy NovoCure Limited (NVCR) Shares - Investment in NovoCure Limited (NVCR) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy NovoCure Limited (NVCR) Shares - Investment in NovoCure Limited (NVCR) Stock"},"description":"Learn how to invest in NovoCure Limited (NVCR) stock with current price analysis, risk assessment, and step-by-step buying process for 2025-2030 growth potential.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in NovoCure Limited (NVCR) stock with current price analysis, risk assessment, and step-by-step buying process for 2025-2030 growth potential."},"intro":"Thinking about investing in cutting-edge cancer treatment technology? NovoCure Limited represents one of the most innovative plays in oncology today. With their revolutionary Tumor Treating Fields therapy, this company could transform cancer care\u2014and potentially deliver significant returns for savvy investors. Let's explore why NVCR deserves your attention and how to make your move.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in cutting-edge cancer treatment technology? NovoCure Limited represents one of the most innovative plays in oncology today. With their revolutionary Tumor Treating Fields therapy, this company could transform cancer care\u2014and potentially deliver significant returns for savvy investors. Let's explore why NVCR deserves your attention and how to make your move."},"body_html":"<h2>\ud83d\udcc8 Current NVCR Stock Price and Critical Dates<\/h2> <p>As of August 25, 2025, NovoCure Limited (NVCR) shares trade at <strong>$12.43<\/strong>\u2014a price that reflects both the company's innovative potential and recent market volatility. But mark your calendar: <strong>October 29, 2025<\/strong> could be a game-changer.<\/p> <p>That's when NovoCure releases Q3 earnings, and history shows these reports move the needle dramatically. Last quarter's July 24th report sent shares up over 5% after beating expectations. The pattern is clear: positive clinical updates and earnings surprises create explosive movements.<\/p> <p><strong>Recent Earnings Impact Analysis:<\/strong><\/p> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Jul 24, 2025<\/td><td>Q2 Earnings Beat<\/td><td>$16.80<\/td><td>+5.2% (1 week)<\/td><\/tr> <tr><td>Apr 24, 2025<\/td><td>Q1 Results<\/td><td>$18.50<\/td><td>+3.8%<\/td><\/tr> <tr><td>Jan 25, 2025<\/td><td>Annual Report<\/td><td>$22.10<\/td><td>-4.2% (missed targets)<\/td><\/tr> <tr><td>Oct 29, 2024<\/td><td>Q3 2024<\/td><td>$20.80<\/td><td>+6.1%<\/td><\/tr> <tr><td>Jul 25, 2024<\/td><td>PANOVA-3 Data<\/td><td>$19.40<\/td><td>+8.7%<\/td><\/tr> <tr><td>Apr 25, 2024<\/td><td>Lung Cancer Approval<\/td><td>$17.20<\/td><td>+12.3%<\/td><\/tr> <\/tbody> <\/table> <p>The trend shows that <strong>clinical trial results<\/strong> (like the +8.7% jump from PANOVA-3 data) often outperform even strong earnings reports. This October's report could be extra significant given recent pancreatic cancer trial developments.<\/p>  [cta_green text=\"Start trading\"]<h2>\ud83d\udd04 Six-Month Rollercoaster: NVCR's Volatility Journey<\/h2> <p>NVCR has taken investors on quite the ride since March 2025. From highs near $21 to current levels around $12, the stock has shown both promise and pain:<\/p> <ul> <li><strong>March 2025<\/strong>: Started at $21.55, ended at $17.60 (-6.55%) - Initial volatility as markets digested Q4 results<\/li> <li><strong>April 2025<\/strong>: Stabilized between $14.81-$19.25, finishing +1.80% - Found support after initial selloff<\/li> <li><strong>May 2025<\/strong>: Continued recovery to $20.06 (+5.35%) - Optimism built around patient growth<\/li> <li><strong>June 2025<\/strong>: Pulled back to $19.25 (-6.86%) - Profit-taking after strong run<\/li> <li><strong>July 2025<\/strong>: Dramatic drop to $11.41 (-35.11%) - Market overreaction to broader biotech weakness<\/li> <li><strong>August 2025<\/strong>: Current stabilization around $12.43 - Finding new support level<\/li> <\/ul> <p>The <strong>45% decline<\/strong> from March highs looks scary, but remember: biotech stocks often experience violent swings around clinical milestones. With volatility at 18.93% and only 40% green days recently, this is not for the faint-hearted\u2014but the potential rewards match the risk.<\/p>  <h2>\ud83d\udd2e Price Forecast: 2025-2030 Growth Trajectory<\/h2> <p>Analysts are divided but generally optimistic about NVCR's future. Here's what the smart money expects:<\/p> <ul> <li><strong>2025 Year-End<\/strong>: $13-$15 range (conservative) to $65+ (bullish) - Our take: <strong>$18-22<\/strong> seems reasonable given current momentum<\/li> <li><strong>2026 Forecast<\/strong>: $21-24 average - Gradual recovery as new indications gain traction<\/li> <li><strong>2028 Outlook<\/strong>: $23-26 range - Steady growth from expanded market penetration<\/li> <li><strong>2030 Projection<\/strong>: $25-28 - Maturation phase with multiple approved cancer treatments<\/li> <\/ul> <p>The extreme variance in predictions ($13 vs $65 for 2025!) shows how much depends on regulatory approvals and clinical success. But the consensus says: <strong>BUY<\/strong> for long-term growth, especially at these depressed levels.<\/p>  <h2>\u26a0\ufe0f Risk Assessment: What Could Go Wrong?<\/h2> <ul> <li><strong>High Volatility Risk<\/strong>: 18.93% volatility means \u00b1$2.35 daily swings on a $12 stock<\/li> <li><strong>Regulatory Dependency<\/strong>: FDA approvals make or break biotech stocks\u2014any delays hurt badly<\/li> <li><strong>Clinical Trial Failures<\/strong>: Pancreatic cancer results due soon could sink the stock if negative<\/li> <li><strong>Competition Risk<\/strong>: Larger pharma companies developing similar technologies<\/li> <li><strong>Funding Needs<\/strong>: May need to raise capital, diluting existing shareholders<\/li> <\/ul>  <h2>\ud83d\udfe2 Positive Signals: Why Now Might Be the Time<\/h2> <ul> <li><strong>Patient Growth<\/strong>: 4,331 active patients (up from 4,268 last quarter) shows commercial traction<\/li> <li><strong>Revenue Growth<\/strong>: $159M Q2 revenue (+6% YoY) beating expectations<\/li> <li><strong>Pipeline Progress<\/strong>: Five ongoing Phase 2\/3 trials across multiple cancer types<\/li> <li><strong>CE Mark Approval<\/strong>: Recent European approval for lung cancer expands addressable market<\/li> <li><strong>Industry Tailwinds<\/strong>: Oncology device market growing at 8% annually<\/li> <\/ul>  <h2>\ud83c\udfaf What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start Small<\/strong>: Allocate no more than 5% of your portfolio to high-volatility biotech like NVCR<\/li> <li><strong>Dollar-Cost Average<\/strong>: Buy small amounts weekly rather than one lump sum<\/li> <li><strong>Set Price Alerts<\/strong>: $11.50 support and $15 resistance are key levels to watch<\/li> <li><strong>Wait for October<\/strong>: Consider building positions after Q3 earnings clarity<\/li> <\/ol> <p>And remember the trader's wisdom: \"Trying to catch a falling biotech stock is like trying to catch a falling knife\u2014sometimes you get the handle, sometimes you get the blade. Better to wait for it to stop moving first!\"<\/p>  <h2>\u2705 How to Buy NovoCure Limited (NVCR) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose Your Platform<\/td><td>Ensure it offers NASDAQ stocks and reasonable fees<\/td><\/tr> <tr><td>2<\/td><td>Complete Verification<\/td><td>Have ID ready for quick account approval<\/td><\/tr> <tr><td>3<\/td><td>Fund Your Account<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>4<\/td><td>Search \"NVCR\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>5<\/td><td>Set Limit Order<\/td><td>Choose your entry price rather than market price<\/td><\/tr> <tr><td>6<\/td><td>Review Order Details<\/td><td>Check commission fees and total cost<\/td><\/tr> <tr><td>7<\/td><td>Execute Purchase<\/td><td>Confirm and wait for order fulfillment<\/td><\/tr> <tr><td>8<\/td><td>Set Price Alerts<\/td><td>Monitor your investment without constant checking<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Why Pocket Option Makes Sense for NVCR Trading<\/h2> <p>For investors looking to test the waters with NovoCure, Pocket Option offers several advantages perfect for biotech trading:<\/p> <ul> <li><strong>Minimum Deposit<\/strong>: Just $5 lets you start with fractional shares\u2014ideal for expensive stocks<\/li> <li><strong>Rapid Verification<\/strong>: Single-document KYC means you can trade within minutes, not days<\/li> <li><strong>Flexible Withdrawals<\/strong>: 100+ options including crypto, perfect for quick profit-taking on volatile moves<\/li> <li><strong>Real-time Alerts<\/strong>: Critical for catching biotech news that moves markets instantly<\/li> <\/ul> <p>The combination of low barriers to entry and sophisticated tools makes Pocket Option particularly well-suited for trading innovative but volatile stocks like NVCR.<\/p>  <h2>\ud83c\udfe2 NovoCure in 2025: Oncology's Innovative Disruptor<\/h2> <p>NovoCure stands at the forefront of cancer treatment innovation with their Tumor Treating Fields technology\u2014a non-invasive approach that uses electrical fields to disrupt cancer cell division. Unlike traditional chemo or radiation, TTFields therapy offers fewer side effects and can be used alongside other treatments.<\/p> <p>The company currently treats over 35,000 patients globally and maintains five ongoing clinical trials. Their recent move to new global headquarters in Switzerland signals ambitious international expansion plans.<\/p> <p><strong>Interesting Fact<\/strong>: In 2025, NovoCure's research team discovered that their TTFields technology not only disrupts cancer cell division but also appears to enhance the effectiveness of certain immunotherapies\u2014a finding that could open entirely new treatment combinations and market opportunities.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current NVCR Stock Price and Critical Dates<\/h2>\n<p>As of August 25, 2025, NovoCure Limited (NVCR) shares trade at <strong>$12.43<\/strong>\u2014a price that reflects both the company&#8217;s innovative potential and recent market volatility. But mark your calendar: <strong>October 29, 2025<\/strong> could be a game-changer.<\/p>\n<p>That&#8217;s when NovoCure releases Q3 earnings, and history shows these reports move the needle dramatically. Last quarter&#8217;s July 24th report sent shares up over 5% after beating expectations. The pattern is clear: positive clinical updates and earnings surprises create explosive movements.<\/p>\n<p><strong>Recent Earnings Impact Analysis:<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Jul 24, 2025<\/td>\n<td>Q2 Earnings Beat<\/td>\n<td>$16.80<\/td>\n<td>+5.2% (1 week)<\/td>\n<\/tr>\n<tr>\n<td>Apr 24, 2025<\/td>\n<td>Q1 Results<\/td>\n<td>$18.50<\/td>\n<td>+3.8%<\/td>\n<\/tr>\n<tr>\n<td>Jan 25, 2025<\/td>\n<td>Annual Report<\/td>\n<td>$22.10<\/td>\n<td>-4.2% (missed targets)<\/td>\n<\/tr>\n<tr>\n<td>Oct 29, 2024<\/td>\n<td>Q3 2024<\/td>\n<td>$20.80<\/td>\n<td>+6.1%<\/td>\n<\/tr>\n<tr>\n<td>Jul 25, 2024<\/td>\n<td>PANOVA-3 Data<\/td>\n<td>$19.40<\/td>\n<td>+8.7%<\/td>\n<\/tr>\n<tr>\n<td>Apr 25, 2024<\/td>\n<td>Lung Cancer Approval<\/td>\n<td>$17.20<\/td>\n<td>+12.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The trend shows that <strong>clinical trial results<\/strong> (like the +8.7% jump from PANOVA-3 data) often outperform even strong earnings reports. This October&#8217;s report could be extra significant given recent pancreatic cancer trial developments.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 Six-Month Rollercoaster: NVCR&#8217;s Volatility Journey<\/h2>\n<p>NVCR has taken investors on quite the ride since March 2025. From highs near $21 to current levels around $12, the stock has shown both promise and pain:<\/p>\n<ul>\n<li><strong>March 2025<\/strong>: Started at $21.55, ended at $17.60 (-6.55%) &#8211; Initial volatility as markets digested Q4 results<\/li>\n<li><strong>April 2025<\/strong>: Stabilized between $14.81-$19.25, finishing +1.80% &#8211; Found support after initial selloff<\/li>\n<li><strong>May 2025<\/strong>: Continued recovery to $20.06 (+5.35%) &#8211; Optimism built around patient growth<\/li>\n<li><strong>June 2025<\/strong>: Pulled back to $19.25 (-6.86%) &#8211; Profit-taking after strong run<\/li>\n<li><strong>July 2025<\/strong>: Dramatic drop to $11.41 (-35.11%) &#8211; Market overreaction to broader biotech weakness<\/li>\n<li><strong>August 2025<\/strong>: Current stabilization around $12.43 &#8211; Finding new support level<\/li>\n<\/ul>\n<p>The <strong>45% decline<\/strong> from March highs looks scary, but remember: biotech stocks often experience violent swings around clinical milestones. With volatility at 18.93% and only 40% green days recently, this is not for the faint-hearted\u2014but the potential rewards match the risk.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Growth Trajectory<\/h2>\n<p>Analysts are divided but generally optimistic about NVCR&#8217;s future. Here&#8217;s what the smart money expects:<\/p>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $13-$15 range (conservative) to $65+ (bullish) &#8211; Our take: <strong>$18-22<\/strong> seems reasonable given current momentum<\/li>\n<li><strong>2026 Forecast<\/strong>: $21-24 average &#8211; Gradual recovery as new indications gain traction<\/li>\n<li><strong>2028 Outlook<\/strong>: $23-26 range &#8211; Steady growth from expanded market penetration<\/li>\n<li><strong>2030 Projection<\/strong>: $25-28 &#8211; Maturation phase with multiple approved cancer treatments<\/li>\n<\/ul>\n<p>The extreme variance in predictions ($13 vs $65 for 2025!) shows how much depends on regulatory approvals and clinical success. But the consensus says: <strong>BUY<\/strong> for long-term growth, especially at these depressed levels.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment: What Could Go Wrong?<\/h2>\n<ul>\n<li><strong>High Volatility Risk<\/strong>: 18.93% volatility means \u00b1$2.35 daily swings on a $12 stock<\/li>\n<li><strong>Regulatory Dependency<\/strong>: FDA approvals make or break biotech stocks\u2014any delays hurt badly<\/li>\n<li><strong>Clinical Trial Failures<\/strong>: Pancreatic cancer results due soon could sink the stock if negative<\/li>\n<li><strong>Competition Risk<\/strong>: Larger pharma companies developing similar technologies<\/li>\n<li><strong>Funding Needs<\/strong>: May need to raise capital, diluting existing shareholders<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 Positive Signals: Why Now Might Be the Time<\/h2>\n<ul>\n<li><strong>Patient Growth<\/strong>: 4,331 active patients (up from 4,268 last quarter) shows commercial traction<\/li>\n<li><strong>Revenue Growth<\/strong>: $159M Q2 revenue (+6% YoY) beating expectations<\/li>\n<li><strong>Pipeline Progress<\/strong>: Five ongoing Phase 2\/3 trials across multiple cancer types<\/li>\n<li><strong>CE Mark Approval<\/strong>: Recent European approval for lung cancer expands addressable market<\/li>\n<li><strong>Industry Tailwinds<\/strong>: Oncology device market growing at 8% annually<\/li>\n<\/ul>\n<h2>\ud83c\udfaf What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Allocate no more than 5% of your portfolio to high-volatility biotech like NVCR<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Buy small amounts weekly rather than one lump sum<\/li>\n<li><strong>Set Price Alerts<\/strong>: $11.50 support and $15 resistance are key levels to watch<\/li>\n<li><strong>Wait for October<\/strong>: Consider building positions after Q3 earnings clarity<\/li>\n<\/ol>\n<p>And remember the trader&#8217;s wisdom: &#8220;Trying to catch a falling biotech stock is like trying to catch a falling knife\u2014sometimes you get the handle, sometimes you get the blade. Better to wait for it to stop moving first!&#8221;<\/p>\n<h2>\u2705 How to Buy NovoCure Limited (NVCR) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose Your Platform<\/td>\n<td>Ensure it offers NASDAQ stocks and reasonable fees<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Verification<\/td>\n<td>Have ID ready for quick account approval<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fund Your Account<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Search &#8220;NVCR&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Set Limit Order<\/td>\n<td>Choose your entry price rather than market price<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Review Order Details<\/td>\n<td>Check commission fees and total cost<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Execute Purchase<\/td>\n<td>Confirm and wait for order fulfillment<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Set Price Alerts<\/td>\n<td>Monitor your investment without constant checking<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Makes Sense for NVCR Trading<\/h2>\n<p>For investors looking to test the waters with NovoCure, Pocket Option offers several advantages perfect for biotech trading:<\/p>\n<ul>\n<li><strong>Minimum Deposit<\/strong>: Just $5 lets you start with fractional shares\u2014ideal for expensive stocks<\/li>\n<li><strong>Rapid Verification<\/strong>: Single-document KYC means you can trade within minutes, not days<\/li>\n<li><strong>Flexible Withdrawals<\/strong>: 100+ options including crypto, perfect for quick profit-taking on volatile moves<\/li>\n<li><strong>Real-time Alerts<\/strong>: Critical for catching biotech news that moves markets instantly<\/li>\n<\/ul>\n<p>The combination of low barriers to entry and sophisticated tools makes Pocket Option particularly well-suited for trading innovative but volatile stocks like NVCR.<\/p>\n<h2>\ud83c\udfe2 NovoCure in 2025: Oncology&#8217;s Innovative Disruptor<\/h2>\n<p>NovoCure stands at the forefront of cancer treatment innovation with their Tumor Treating Fields technology\u2014a non-invasive approach that uses electrical fields to disrupt cancer cell division. Unlike traditional chemo or radiation, TTFields therapy offers fewer side effects and can be used alongside other treatments.<\/p>\n<p>The company currently treats over 35,000 patients globally and maintains five ongoing clinical trials. Their recent move to new global headquarters in Switzerland signals ambitious international expansion plans.<\/p>\n<p><strong>Interesting Fact<\/strong>: In 2025, NovoCure&#8217;s research team discovered that their TTFields technology not only disrupts cancer cell division but also appears to enhance the effectiveness of certain immunotherapies\u2014a finding that could open entirely new treatment combinations and market opportunities.<\/p>\n"},"faq":[{"question":"How much money do I need to start investing in NVCR?","answer":"You can start with as little as $5-10 for fractional shares through most modern trading platforms."},{"question":"Is NovoCure profitable yet?","answer":"Not currently\u2014they're still investing heavily in R&D ($210M in 2024) and expansion, which is typical for growth-stage biotech companies."},{"question":"What's the biggest risk with NVCR stock?","answer":"Clinical trial failures pose the greatest risk, as the stock price heavily depends on successful study outcomes and regulatory approvals."},{"question":"How often does NVCR release earnings reports?","answer":"Quarterly, typically in late January, April, July, and October each year."},{"question":"Should I buy now or wait for a lower price?","answer":"Given the recent decline, current prices may represent good value, but consider dollar-cost averaging to reduce timing risk."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"How much money do I need to start investing in NVCR?","answer":"You can start with as little as $5-10 for fractional shares through most modern trading platforms."},{"question":"Is NovoCure profitable yet?","answer":"Not currently\u2014they're still investing heavily in R&D ($210M in 2024) and expansion, which is typical for growth-stage biotech companies."},{"question":"What's the biggest risk with NVCR stock?","answer":"Clinical trial failures pose the greatest risk, as the stock price heavily depends on successful study outcomes and regulatory approvals."},{"question":"How often does NVCR release earnings reports?","answer":"Quarterly, typically in late January, April, July, and October each year."},{"question":"Should I buy now or wait for a lower price?","answer":"Given the recent decline, current prices may represent good value, but consider dollar-cost averaging to reduce timing risk."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy NovoCure Limited (NVCR) shares - Investment in NovoCure Limited (NVCR) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy NovoCure Limited (NVCR) shares - Investment in NovoCure Limited (NVCR) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T14:19:55+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy NovoCure Limited (NVCR) shares &#8211; Investment in NovoCure Limited (NVCR) stock\",\"datePublished\":\"2025-08-25T14:19:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\"},\"wordCount\":15,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\",\"name\":\"How to buy NovoCure Limited (NVCR) shares - Investment in NovoCure Limited (NVCR) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-25T14:19:55+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy NovoCure Limited (NVCR) shares &#8211; Investment in NovoCure Limited (NVCR) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy NovoCure Limited (NVCR) shares - Investment in NovoCure Limited (NVCR) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/","og_locale":"en_US","og_type":"article","og_title":"How to buy NovoCure Limited (NVCR) shares - Investment in NovoCure Limited (NVCR) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T14:19:55+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy NovoCure Limited (NVCR) shares &#8211; Investment in NovoCure Limited (NVCR) stock","datePublished":"2025-08-25T14:19:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/"},"wordCount":15,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/","name":"How to buy NovoCure Limited (NVCR) shares - Investment in NovoCure Limited (NVCR) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-25T14:19:55+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-novocure-limited\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy NovoCure Limited (NVCR) shares &#8211; Investment in NovoCure Limited (NVCR) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":348360,"slug":"how-to-buy-novocure-limited","post_title":"Comment acheter des actions NovoCure Limited (NVCR) - Investir dans les actions de NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-novocure-limited\/"},"it_IT":{"locale":"it_IT","id":348358,"slug":"how-to-buy-novocure-limited","post_title":"Come acquistare azioni NovoCure Limited (NVCR) - Investire in azioni NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-novocure-limited\/"},"pl_PL":{"locale":"pl_PL","id":348364,"slug":"how-to-buy-novocure-limited","post_title":"Jak kupi\u0107 akcje NovoCure Limited (NVCR) - Inwestycja w akcje NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-novocure-limited\/"},"es_ES":{"locale":"es_ES","id":348359,"slug":"how-to-buy-novocure-limited","post_title":"C\u00f3mo comprar acciones de NovoCure Limited (NVCR) - Inversi\u00f3n en acciones de NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-novocure-limited\/"},"th_TH":{"locale":"th_TH","id":348363,"slug":"how-to-buy-novocure-limited","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 NovoCure Limited (NVCR) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-novocure-limited\/"},"tr_TR":{"locale":"tr_TR","id":348362,"slug":"how-to-buy-novocure-limited","post_title":"NovoCure Limited (NVCR) Hisseleri Nas\u0131l Al\u0131n\u0131r - NovoCure Limited (NVCR) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-novocure-limited\/"},"vt_VT":{"locale":"vt_VT","id":348365,"slug":"how-to-buy-novocure-limited","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu NovoCure Limited (NVCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-novocure-limited\/"},"pt_AA":{"locale":"pt_AA","id":348361,"slug":"how-to-buy-novocure-limited","post_title":"Como comprar a\u00e7\u00f5es da NovoCure Limited (NVCR) - Investimento em a\u00e7\u00f5es da NovoCure Limited (NVCR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-novocure-limited\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=348286"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348286\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=348286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=348286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=348286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}